Lineage Cell Therapeutics (LCTX) Stock Analysis & AI Equity Report
Lineage Cell Therapeutics (LCTX) overview
Lineage Cell Therapeutics (LCTX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 14.6m and operating profit of USD -36.6m; the year-end share price was 1.67 USD and market capitalisation was USD 406m. Lineage Cell Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Lineage Cell Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell replacement therapies for conditions associated with lost or dysfunctional cells. Its programs use differentiated cells derived from pluripotent cell lines, supported by its AlloSCOPE manufacturing platform. The portfolio includes OpRegen, an allogeneic retinal pigment epithelial cell therapy in Phase 2a development with Roche and Genentech for geographic atrophy secondary to dry age-related macular degeneration.
Generate the Lineage Cell Therapeutics report
Lineage Cell Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Lineage Cell Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Lineage Cell Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.